

## **Temporary Production Interruption at Allston Landing Manufacturing Facility Has No Impact on Aldurazyme**

PRNewswire-FirstCall

NOVATO, Calif.

BioMarin Pharmaceutical Inc. announced today that the temporary interruption of bulk production at Genzyme's Allston Landing manufacturing facility is not expected to have any impact on Aldurazyme supply or revenue to BioMarin or Genzyme. The last Aldurazyme fill at the Allston Landing facility was in September 2008. BioMarin has a total of approximately ten months of vialled inventory on hand, utilizes a second fill finish supplier and a third is expected to be qualified later this year. BioMarin manufactures Aldurazyme bulk material at its Novato facility and has adequate inventory in bulk and vialled form to meet expected ongoing Aldurazyme demand on a worldwide basis.

### About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is in clinical development for the treatment of PKU and

GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase 1/2 clinical development for the treatment of MPS IVA. For additional information, please visit [www.BMRN.com](http://www.BMRN.com). Information on BioMarin's website is not incorporated by reference into this press release.

## Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the development of its product candidate PEG-PAL, the timing, design, conduct and expectations related to the PEG-PAL clinical trials, and expectations regarding filings with regulatory agencies. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the results of current and planned clinical trials related to PEG-PAL; the content and timing of decisions by the U.S. Food and Drug Administration and other regulatory agencies, particularly with respect to PEG-PAL, and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2008 Annual Report on Form 10-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R) are a registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Contact:

Investors:

Eugenia Shen

BioMarin Pharmaceutical Inc.

(415) 506-6570

Media:

Susan Berg

BioMarin Pharmaceutical Inc.

(415) 506-6594

First Call Analyst:

FCMN Contact: [eshen@bmrn.com](mailto:eshen@bmrn.com)

SOURCE: BioMarin Pharmaceutical Inc.

CONTACT: Investors, Eugenia Shen, +1-415-506-6570, or Media, Susan Berg, +1-415-506-6594, both of BioMarin Pharmaceutical Inc.

Web Site: <http://www.bmrn.com/>

---

<https://investors.biomin.com/2009-06-16-Temporary-Production-Interruption-at-Allston-Landing-Manufacturing-Facility-Has-No-Impact-on-Aldurazyme>